BAVA Stock Overview
Develops, manufactures, and commercializes life-saving vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 22.61 |
| 52 Week High | DKK 39.43 |
| 52 Week Low | DKK 19.35 |
| Beta | 1.58 |
| 11 Month Change | -23.02% |
| 3 Month Change | -37.92% |
| 1 Year Change | 8.86% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAVA | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -19.1% | -5.2% | 0.9% |
| 1Y | 8.9% | 2.6% | 1.5% |
Return vs Industry: BAVA exceeded the Austrian Biotechs industry which returned 2.6% over the past year.
Return vs Market: BAVA exceeded the Austrian Market which returned 1.5% over the past year.
Price Volatility
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.3% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: BAVA's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: BAVA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,609 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
| BAVA fundamental statistics | |
|---|---|
| Market cap | €1.78b |
| Earnings (TTM) | €149.95m |
| Revenue (TTM) | €813.68m |
11.9x
P/E Ratio2.2x
P/S RatioIs BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAVA income statement (TTM) | |
|---|---|
| Revenue | DKK 6.07b |
| Cost of Revenue | DKK 2.33b |
| Gross Profit | DKK 3.74b |
| Other Expenses | DKK 2.62b |
| Earnings | DKK 1.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | 14.24 |
| Gross Margin | 61.57% |
| Net Profit Margin | 18.43% |
| Debt/Equity Ratio | 0.1% |
How did BAVA perform over the long term?
See historical performance and comparison